SCHEMBL219554

SCHEMBL219554

CC(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 4/20 0.71
ADORA1 P30542 3/20 0.71
SMN1; SMN2 Q16637 3/20 0.71
P2RY2 P41231 3/20 0.71
SRC P12931 2/20 0.71
DNPH1 O43598 1/20 0.71
PRKAB2 O43741 1/20 0.71
TRPM2 O94759 1/20 0.71
LDHA P00338 1/20 0.71
ADRB2 P07550 1/20 0.71
FBP1 P09467 1/20 0.71
PRKAG1 P54619 1/20 0.71
PRKAA2 P54646 1/20 0.71
PDE4D Q08499 1/20 0.71
KCNH2 Q12809 1/20 0.71
PRKAA1 Q13131 1/20 0.71
PDE3A Q14432 1/20 0.71
TAS1R3 Q7RTX0 1/20 0.71
TAS1R1 Q7RTX1 1/20 0.71
P2RY11 Q96G91 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5550634 1.00 P2RY1 (0.71) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL11584743 1.00 P2RY1 (0.71) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL31001632 1.00 P2RY1 (0.71) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL1069794 0.92 P2RY1 (0.66) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL23982336 0.91 MARS1 (0.60) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL6237498 0.91 MARS1 (0.60) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL6237505 0.91 MARS1 (0.60) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL1757017 0.90 ADORA1 (0.73) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL2463542 0.90 PRKACA (0.73) P2RY1ADORA1SMN1; SMN2P2RY2SRC
SCHEMBL9426538 0.90 PRKACA (0.73) P2RY1ADORA1SMN1; SMN2P2RY2SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118580307-B Pro.AH8 acetyl hexapeptide-8 with tightening and anti-wrinkle effects, and preparation method and application thereof 广东合鸣生物科技有限公司 2025-05-27 CN claimed
CN-118580307-A Pro.AH8 acetyl hexapeptide-8 with tightening and anti-wrinkle effects, and preparation method and application thereof 广东合鸣生物科技有限公司 2024-09-03 CN claimed
CN-113521091-A Pharmaceutical composition for preventing or treating heart diseases and application thereof 睿纳(珠海横琴)生物科技有限公司 2021-10-22 CN claimed
US-11149271-B2 Method and pharmaceutical composition for treating cancer INCREASEPHARM (HK) LIMITED (HK) 2021-10-19 US claimed
CN-110870871-B Methods and pharmaceutical compositions for treating cancer 澳门科技大学 2021-09-07 CN claimed
WO-2021035391-A1 USE OF TRANSFER RNA MOLECULE AND FRAGMENT THEREOF IN PREVENTION OR TREATMENT OF HEART DISEASE 澳门科技大学 2021-03-04 WO claimed
US-20210052630-A1 Methods and Compositions for Preventing or Treating Heart Disease MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2021-02-25 US claimed
CN-111419867-A Use of transport RNA molecules and fragments thereof for preventing or treating cardiac diseases 澳门科技大学 2020-07-17 CN claimed
CN-110870871-A Methods and pharmaceutical compositions for treating cancer 澳门科技大学 2020-03-10 CN claimed
US-20200071695-A1 METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER INCREASEPHARM (HK) LIMITED (HK) 2020-03-05 US claimed
US-8088752-B2 Methods for metabolic modulation VDF FUTURECEUTICALS, INC. (US) 2012-01-03 US claimed
WO-2026107144-A1 RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2026-05-21 WO disclosed
CN-118580307-B Pro.AH8 acetyl hexapeptide-8 with tightening and anti-wrinkle effects, and preparation method and application thereof 广东合鸣生物科技有限公司 2025-05-27 CN disclosed
WO-2025072615-A1 IMPROVED METHODS OF MAKING RNA BY SPLINTED LIGATION AND COMPOSITIONS THEREOF ORBITAL THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
CN-118580307-A Pro.AH8 acetyl hexapeptide-8 with tightening and anti-wrinkle effects, and preparation method and application thereof 广东合鸣生物科技有限公司 2024-09-03 CN disclosed
WO-1997030713-A1 METHOD AND COMPOSITION FOR INHIBITING CELLULAR IRREVERSIBLE CHANGES DUE TO STRESS GALILEO LABORATORIES, INC. (US) 1997-08-28 WO disclosed
EP-0670845-A1 PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE SCHERING AKTIENGESELLSCHAFT (DE) 1995-09-13 EP disclosed
EP-0666910-A1 METHOD OF CLEAVING SPECIFIC STRANDS OF RNA THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-08-16 EP disclosed
WO-1994012514-A1 PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE SCHERING AKTIENGESELLSCHAFT (DE) 1994-06-09 WO disclosed
WO-1994009129-A2 METHOD OF CLEAVING SPECIFIC STRANDS OF RNA THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-04-28 WO disclosed